Charles River Laboratories’ acquisition of an additional 41% stake in Noveprim Limited’s operations in Mauritius for USD 211.6 million

Lead party: Charles River Laboratories International, Inc. (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: Noveprim Limited (private company) · Sector: Industrials, Research & Consulting Services · Countries of operation: Mauritius Transaction type: Investment · Asset class: Corporate Transactions · Strategy: Buyout · Instrument: Equity · Deal amount:…


Lead party: Charles River Laboratories International, Inc. (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: Noveprim Limited (private company) · Sector: Industrials, Research & Consulting Services · Countries of operation: Mauritius

Transaction type: Investment · Asset class: Corporate Transactions · Strategy: Buyout · Instrument: Equity · Deal amount: US$211.6m · Equity stake: 0.41% · Implied EV: US$516.1m

Lead investor/buyer: Charles River Laboratories International, Inc. · Investors/buyers: Charles River Laboratories International, Inc.

Legal advisers: not identified in the source record.

Source: announced 30 November 2023. Original announcement: ir.criver.com.